Literature DB >> 3465487

Pronounced increases in the concentration of an ovarian tumor marker, CA-125, in serum of a healthy subject during menstruation.

W Mastropaolo, Z Fernandez, E L Miller.   

Abstract

CA-125 is a glycoprotein associated with various ovarian tumors. A commercial radioimmunoassay involving a monoclonal antibody is available for it. In our laboratory, a normal-value study was conducted as part of a routine evaluation of this assay. One healthy subject had a serum CA-125 concentration greater than 300 kU/L, more than eightfold the upper limit of normal (35 kU/L). This increase, which coincided with the onset of the menstrual period, subsided to within the normal range by the end of the menstrual cycle. The half-life of CA-125, calculated from this decrease, was 6.4 days. Similar observations were made in the same subject over several menstrual cycles. Results of clinical and ultrasound examinations of the subject for ovarian tumors were negative. No clinical evidence of malignancy was present eight months after the initial discovery of an increased CA-125. None of the other 39 healthy subjects had a CA-125 value greater than 51 kU/L. Five of these subjects had CA-125 determined several times during their menstrual cycles; none exhibited pronounced variations in CA-125 concentrations. Evidently CA-125 can be extremely increased in a healthy woman, and possible effects of the menstrual period on serum CA-125 concentrations should be considered in pre-menopausal patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3465487

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  7 in total

1.  Immunoscintigraphy using CA 125 antibodies in the management of ovarian cancer.

Authors:  J Brökelmann; A Bockisch; J Vogel; J Reinsberg; P Oehr; H J Biersack; D Krebs
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

2.  Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations.

Authors:  Sharon S Hori; Sanjiv S Gambhir
Journal:  Sci Transl Med       Date:  2011-11-16       Impact factor: 17.956

3.  Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays.

Authors:  Madhumita Chatterjee; Saroj Mohapatra; Alexei Ionan; Gagandeep Bawa; Rouba Ali-Fehmi; Xiaoju Wang; James Nowak; Bin Ye; Fatimah A Nahhas; Karen Lu; Steven S Witkin; David Fishman; Adnan Munkarah; Robert Morris; Nancy K Levin; Natalie N Shirley; Gerard Tromp; Judith Abrams; Sorin Draghici; Michael A Tainsky
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

4.  Prognostic significance of phosphatase of regenerating liver-3 expression in ovarian cancer.

Authors:  Tingting Ren; Beihai Jiang; Xiaofang Xing; Bin Dong; Lirong Peng; Lin Meng; Huiyu Xu; Chengchao Shou
Journal:  Pathol Oncol Res       Date:  2009-02-27       Impact factor: 3.201

5.  p53-autoantibody may be more sensitive than CA-125 in monitoring microscopic and macroscopic residual disease after primary therapy for epithelial ovarian cancer.

Authors:  Norman Häfner; Kristin Nicolaus; Stefanie Weiss; Manfred Frey; Herbert Diebolder; Matthias Rengsberger; Matthias Dürst; Ingo B Runnebaum
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-11       Impact factor: 4.553

6.  Relationship between serum CA 125 levels, endometrial thickness and corpus luteum function in different stages of ovarian activity.

Authors:  G Ozakşit; N O Turhan; H Oral; N Doğu; O Gökmen
Journal:  J Endocrinol Invest       Date:  1993-03       Impact factor: 4.256

7.  Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes.

Authors:  Amelie M Lutz; Juergen K Willmann; Frank V Cochran; Pritha Ray; Sanjiv S Gambhir
Journal:  PLoS Med       Date:  2008-08-19       Impact factor: 11.069

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.